← Association for Accessible Medicines
FDARulemakingFDA-2023-N-0061

Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act

RIN
—
Last modified
Nov 6, 2024
Comment window
closed 770d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jun 17, 2024 and Jun 17, 2024. 1 other organizations filed here. The comment window closed 770d ago.

What Association for Accessible Medicines filed (1)

Jun 17, 2024· Comment from Association for Accessible Medicines (AAM)· FDA-2023-N-0061-0018

FDA, Please find attached comments from The Association for Accessible Medicines (AAM) regarding Docket No. FDA–2023-N-0061, "Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act; Proposed Rule" Thanks, Scott Kuzner, Ph.D., Senior Director, Sciences and Regulatory Affairs, AAM

View on regulations.gov →

Abstract

Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act

View on regulations.gov →

Co-filers (1)

See everyone who commented →